Frontiers | Mechanisms of Drug Resistance to Targeted Therapy in Malignancies

Mechanisms of Drug Resistance to Targeted Therapy in Malignancies

3,492
Total downloads
10k
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 24 Jan 2024

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

Yu Wang
Shunsuke Shimosaki
Emi Ikebe
Hidekatsu Iha
Jun-ichi Yamamoto
Nichole Fife
Tomonaga Ichikawa
Mitsuo Hori
Masao Ogata
9 more
Kazuhiro Morishita

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

doi 10.3389/fonc.2023.1272528

1,725 views
1 citation

EDITORIAL

Published on 19 Jan 2024

Editorial: Mechanisms of drug resistance to targeted therapy in malignancies

Masatsugu Hamaji

doi 10.3389/fonc.2024.1363808

427 views

ORIGINAL RESEARCH

Published on 03 Jan 2024

PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

Abdul K. Siraj
Pratheesh Kumar Poyil
Divya Padmaja
Sandeep Kumar Parvathareddy
Khadija Alobaisi
Saravanan Thangavel
Roxanne Diaz
Rafia Begum
Osama Almalik
1 more
Khawla S. Al-Kuraya

PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

doi 10.3389/fonc.2023.1286585

1,259 views
1 citation

ORIGINAL RESEARCH

Published on 08 Sep 2023

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

Kristina Breitenecker
Viola Hedrich
Franziska Pupp
Doris Chen
Eva Řezníčková
Gregor Ortmayr
Heidemarie Huber
Gerhard Weber
Lorenz Balcar
1 more
Wolfgang Mikulits

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

doi 10.3389/fonc.2023.1238883

2,081 views
2 citations

ORIGINAL RESEARCH

Published on 21 Aug 2023

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

Chian-Wei Chen
Chien-Yu Lin
Jeng-Shiuan Tsai
Chia-Yin Lin
Chao-Chun Chang
Yi-Ting Yen
Yau-Lin Tseng
Po-Lan Su
Chien-Chung Lin

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

doi 10.3389/fonc.2023.1238876

1,411 views
1 citation

ORIGINAL RESEARCH

Published on 19 Jun 2023

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Jiuhui Xu
Chenglong Chen
Kunkun Sun
Qianyu Shi
Boyang Wang
Yi Huang
Tingting Ren
Xiaodong Tang

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

doi 10.3389/fonc.2023.1192472

1,464 views
3 citations

Share on

Frontiers in Oncology

Frontiers in Oncology

Cancer Molecular Targets and Therapeutics

Impact

10kTopic views
6,489Article views
3,492Article downloads